Prognostic value of the prognostic immune-inflammatory-nutritional score in patients with advanced gastric cancer treated with immunochemotherapy

Table 4 Univariate and multivariate analyses of prognostic factors for progression-free survival

Variables	Univariate		Multivariate
	P value	HR (95%CI)	P value	HR (95%CI)
Gender
Male vs female	0.334	0.83 (0.56-1.22)	0.242	1.27 (0.85-1.91)
Age (years)
≥ 60 vs < 60	0.18	1.30 (0.89-1.91)	0.884	0.97 (0.66-1.44)
BMI (kg/m2)
< 25 vs ≥ 25	0.171	1.38 (0.87-2.19)
CEA (ng/mL)
< 3 vs ≥ 3	0.3	1.22 (0.83-1.80)
CA199 (ng/mL)
< 37 vs ≥ 37	0.103	1.37 (0.94-2.01)
PIIN score
< 25.69 vs ≥ 25.69	0.004	1.82 (1.20-2.76)	0.004	1.88 (1.23-2.87)
ECOG
0 vs 1	0.005	1.80 (1.19-2.73)
TNM staging
III vs IV	< 0.001	2.74 (1.82-4.15)	< 0.001	2.24 (1.44-3.47)
Peritoneal metastasis
No vs yes	0.005	1.74 (1.19-2.56)
Liver metastasis
No vs yes	0.103	1.49 (0.92-2.40)
PD-L1 expression
CPS < 5 vs CPS ≥ 5	< 0.001	0.27 (0.17-0.42)	< 0.001	0.35 (0.22-0.55)
MMR status
pMMR vs dMMR	< 0.001	0.33 (0.19-0.56)	< 0.001	0.35 (0.20-0.63)

BMI: Body mass index; CEA: Carcinoembryonic-antigen; CA199: Carbohydrate antigen 199; PIIN score: Prognostic immune-inflammatory-nutritional score; ECOG: Eastern Cooperative Oncology Group; PD-L1: Programmed death-ligand 1; CPS: Combined positive score; MMR: Mismatch repair; pMMR: Proficient mismatch repair; dMMR: Deficient mismatch repair; HR: Hazard ratio.